Application of Quality by Design Principles to Study the Effect of Coprocessed Materials in the Preparation of Mirtazapine Orodispersible Tablets
Keywords:
mirtazapine, Box-Behnken, ludiflash, pearlitol flash, kleptose HPBAbstract
The aim of this study was to determine the effect of two coprocessed materials in presence and absence of superdisintegrant (kyron T314) in the preparation of mirtazapine orodispersible tablets. Mirtazapine solubility was increased by complexation with kleptose forming an inclusion complex in a ratio 1:1. Quality by Design (QbD) was incorporated to determine the material attributes and the critical quality attributes (CQAs). Box behnken design was applied to study the effect of three independent variables X1: amount of lufiflash, X2: amount of pearlitol flash and X3: % of kyron T314 on two responses, Y1: dissolution after 1 minute and Y2: disintegration time. All formulated ODTs showed disintegration time less than 35 seconds and all formulations showed a notable increase in dissolution rate. Design space was determined from the overlay plot of different variables, X1 and X2 and X3 at two levels of the superdisintegrant. The one with maximum predicted dissolution rate and minimum predicted disintegration time was a formulation containing ludiflash (X1)= 9.25 mg, pearlitol flash (X2= 50 mg) and kyron T314= 3%. This formulation (Test ODT) was prepared and was subjected to in vivo study. Mirtazapine in human plasma was determined by LC-MS/MS and different pharmacokinetic parameters was determined for both test ODT and conventional oral tablet (Remeron). The pharmacokinetic parameters indicated that the two formulations are bioequivalence.
References
. Kaur T, Bhawandeep G, Sandeep K,
Gupta G D. 2011. Mouth dissolving
tablets: a novel approach to drug
delivery. Int J Curr Pharm Res. 3:1‐7.
. Indhumathi D, Rathnam G. 2010. Design
and optimization of orodissolving tablet
of antidepressant drug by
superdisintegrants addition method. Int J
Pharm Sci Rev Res. 2(2):1-8.
. Bhardwaj V, Bansal M, Sharma PK.
Formulation and Evaluation of
Fast Dissolving tablets of amlodipine
besylate using different super
disintegrants and camphor as
sublimating agent. AmEur J Sci Res.
(4):264-269.
. Wagh, MP, Yewale CP, Zate SU,
KothawadePI, Mahale GH. 2010.
Formulation and evaluation of fast
dispersible tablets of aceclofenac using
different superdisintegrants. Int J of
Pharm Sci. 2:154-157.
. Sunita AC, Ankit BC, Tejal AM. 2010.
Excipients Updates for Orally
Disintegrating Dosage Forms. Int J Res
Pharm Sci.1(2):103-107.
. Avachat A, Ahire VJ. 2007.
Characterization and evaluation of spray
dried co-processed excipients and their
application in solid dosage forms. Indian
J Pharm Sci. 69(1):85-90.
. Nagendrakumar D, Raju SA, Shirsand
SB, Para MS. 2010. Design of fast
dissolving granisetronHCL tablets using
novel co-processed superdisintegrants.
Int J PharmaSci Rev Res.1(1):58-62.
. Nachaegari SK, Bansal AK. 2004. Coprocessed excipients for solid dosage
forms. Pharm Technol. 28(1):52-64.
. Sandra K, Silke G, Karl k. 2007.
Ludiflash® ă Easy and reliable
development of orally dispersible tablets.
Excipients & Actives for
Pharma.19:2-4.
. Joshi AA, Duriez X, Added Functionality
Excipients: An Answer to Challenging
Formulations. Pharm. Technol.
Suppl.19:12ă19.
. Bansal AK. 2003. Improved excipients
by solid-state manipulation. The Ind
Pharmacist. 31:9-12.
. Anttila SA, Leinonen EV.2001. A review
of the pharmacological and clinical
profile of mirtazapine.CNS Drug
Rev.7:(3):249-64.
. Food and Drug Administration.
Guidance for industry ICH Q8(R2)
Pharmaceutical Development. (Step 4,
.
. Emad B, Wessam E, Omaima E.2011.
Application of pharmaceuticalQbD for
enhancement of the solubility and
dissolution of a class II BCS drug using
polymeric surfactants and crystallization
inhibitors: development of controlledrelease tablets. AAPS PharmSciTech.
(3):799-810.
. Higuchi T, Connors KA. 1965. Phase
solubility techniques. Adv Anal Chem
Instr. 4:117-212.
. Friedrich H, Nada A, Bodmier R. 2005.
Solid state and dissolution rate
characterization of co-ground mixtures
of nifedipine and hydrophilic carriers.
Drug DevInd Pharm. 31(8):719ă728.
. Swati J, Monali S, Ajay B, Janardan L,
Bhanudas K, Anuruddha C. 2010.
Development of palastile release tablets
of atenolol with swelling and pulsatile
layers. Int J Appl Pharm. 2(3):31-40.
. Patel B, Patel D, Parmar R, Patel C,
Serasiya T, Sanja SD. 2009.
Development and in vitro evaluation of
fast dissolving tablets of glipizide. Int J
Pharm Pharm Sci. 1:145ă50.
. Chaudhari PD, Chaudhari SP, Lanke
SD. 2007. Formulation and in vitro
evaluation of taste masked
orodispersible dosage form of
levocetrizinedihydrochloride. Indian J
Pharm Educ Res. 41:319-28.
. Amit SP, Anil MP. 2013. Quality by
Design (QbD): A new concept for
development of quality pharmaceuticals.
Int J Pharm Qual Ass. 4(2):13-19.
. Vivek K, Reddy H and Murthy RR. 2007.
Investigation of the effect of the solid
lipid matrix on drug entrapment, in-vitro
release, physical stability of olanzapineloaded solid lipid nanoparticles. AAPS
Pharm. Sci. Tech. 8: 1-17.
. Yavuz AE, Haman SB, N. Kazanc N.
Structural and vibrational study of
maprotiline. J MolStruc. 924/926:313-
. Colthup NB, Daly LH, Wiberley SE.
Basic theory. In: Introduction to
the infrared and Raman spectroscopy.
John RF, Kazuo N (eds). Third ed.
Academic press: Boston. pp. 1-89.
. Seda GS, Ayse ES. 2013. Molecular
structure, FTIR, FT-Raman, NMR
studies and first order molecular
hyperpolarizabilities by the DFT method
of mirtazapine and its comparison with
mianserin.
SpectrochimicaActaMolBiomolSpectros.
(1):222-234.
. George SJ, Vasudevan DT. 2012.
Studies on the preparation,
characterization, and solubility of 2-HP-
β-cyclodextrin-meclizine HCl inclusion
complexes. Pharmaceutics. 4(4):220-
. Patil JS, Kadam DV, Marapur SC,
Kamalapur MV. 2010. Inclusion complex
system; A novel technique to improve
the solubility and bioavailability of poorly
soluble drugs: A review. Int J Pharm Sci
Rev Res. 2(2):29-34.
. Marcus EB, Thorsteinn L. 2007.
Cyclodextrins as pharmaceutical
solubilizers. Adv Drug Deliv Rev.
:645ă666.
. Gandhi BR, Mundada AS, Gandhi KR.
Evaluation of Kyron T-314
(Polacrillin Potassium) as a novel super
disintegrant. Int J Drug Deliv.3:109-114.
. Design Expert. Version 8.0.7.1, StateEase Inc., Minneapolis, MN, USA.
